9780898387124 - screening for biological response modifiers: methods and rationale (developments in oncology, 29, band 29) von talmadge, james e.; fidler, isaiah j.; oldham, r.k. (3 Ergebnisse)
Sprache: Englisch
Verlag: Springer, 1985
Serie: Developments in Oncology, Buch 21 von 78. Buch 21 von 78 - Developments in Oncology
- Hardcover
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 116,51
EUR 13,99 VersandVersand von Vereinigtes Königreich nach USAAnzahl: Mehr als 20 verfügbar
Zustand: New. In.
Sprache: Englisch
Verlag: Kluwer Academic Publishers, 1985
Serie: Developments in Oncology, Buch 21 von 78. Buch 21 von 78 - Developments in Oncology
- Hardcover
Anbieter: Kennys Bookstore, Olney, MD, USAKennys Bookstore
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 168,33
EUR 9,18 VersandVersand innerhalb von USAAnzahl: 15 verfügbar
Zustand: New. Series: Developments in Oncology. Num Pages: 194 pages, black & white illustrations. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 12. Weight in Grams: 476. . 1985. Hardback. . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: Springer US, Springer US, 1985
Serie: Developments in Oncology, Buch 21 von 78. Buch 21 von 78 - Developments in Oncology
- Hardcover
Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 114,36
EUR 62,45 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents. The initial observations stimulated a search fo…r new chemotherapeutic agents which might have increased antitumor activity with less toxicity for normal tissues. To aid in the search for these new chemicals and to attempt to distinguish among the many toxic chemicals which might be candidates for clinical studies, the National Cancer Institute, the pharmaceutical industry, and the cancer research laboratories of most Western nations developed systems for 'screening' drugs for antitumor activity. Perhaps the most extensive screening program was established by the National Cancer Institute (1). This screening program has evolved over the last two decades, an evolution which has been repeatedly reviewed (2-5). Various screening programs in use have examined over 500,000 compounds as potential anticancer agents. From these, there are now approximately forty anticancer drugs in clinical use. The utiliy of these compounds and their toxicities have been reviewed on many occasions. It is now apparent that more active and less toxic anticancer drugs are needed. It is also clear that the current screening programs are identifying compounds with similar levels of activity and with continuing moderate to severe toxicity (6).
